Exelixis, Inc. (EXEL) Earnings Call Transcripts

Exelixis, Inc.'s Latest Earnings Call - June 9, 2026

Exelixis, Inc. reported its earnings for Q2 2026, focusing on its strategic transition from a single franchise to a multiple franchise company. The company emphasized its growth in the cabo franchise, particularly in RCC and net indications, and the anticipated launch of Xansa in CRC. Revenue and earnings specifics were not disclosed in the transcript, but management reiterated growth expectations from existing and new indications. Guidance was maintained, with a focus on expanding their pipeline and potential shareholder-friendly activities like buybacks.

Reported metrics

Guidance from management

Management maintained guidance, expecting growth from both RCC and net indications. They are preparing for the Xansa launch and focusing on pipeline expansion.

What management said

Yes. I mean as PJ has talked about in the last couple of earnings calls, the launch is going really well. It's the #1 oral now in kind of a new patient starts in that second line plus segment. And so it's really reflective of the data. And if you look at Cabinet broadly, I think 1 of the things that's most encouraging about it is just the robustness across each of those subcategories or subsegments of patients. And s...

Yes. I mean if you look at kind of just purely the Epi, it's about 20% of RCC. So that's a reasonable proxy, I guess, kind of plus/minus depending on a bunch of different factors. But just looking purely on the segmentation of patients, I think that's a good starting point.

What analysts pressed on

Analysts expressed interest in the sustainability of RCC growth in a mature market and the potential impact of Xansa's pricing and launch timing. There were questions about the ex-U.S. strategy and the non-clear cell RCC market potential.

Main topics on the call

• Strategic Transition — Exelixis is transitioning from a single franchise company to a multiple franchise company, focusing on ADCs, small molecules, and multi-specific antibodies. Management emphasized maximizing the cabo franchise while prepa...
• Cabo Franchise Growth — The cabo franchise continues to grow, with significant contributions from RCC and net indications. Management highlighted its status as the '#1 oral now in kind of a new patient starts in that second line plus segment.'
• Xansa Launch Preparation — Exelixis is preparing for the launch of Xansa in CRC, with plans to launch immediately upon approval. The STELLAR 303 study showed 'statistically and clinically meaningful improvement' in overall survival.
• Pipeline Expansion — The company is investing in its early-stage pipeline and exploring external opportunities to build out additional molecules. Exelixis is conducting multiple pivotal studies to expand its therapeutic offerings.

Read the full Exelixis, Inc. transcript (June 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 147 Exelixis, Inc. earnings call transcripts on record, spanning January 15, 2020 to June 9, 2026. Based on this history, Exelixis, Inc. reports quarterly. The most recent call on file is dated June 9, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

EXEL

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

147

First call

January 15, 2020

Most recent

June 9, 2026

Reporting cadence

quarterly